Article

Impacts of Adipocytokines and Obesity-associated Inflammatory Markers on Apolipoprotein A-1 and B in Patients on Statin Therapy

Received:

Accepted:

Citation:European Cardiology Review 2020;15:e45.

Open access:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Background and aims: Obesity-induced chronic low-grade inflammation is causally associated with insulin resistance leading to dyslipidaemia, which is a residual risk for coronary artery disease in patients on statin therapy. The aim of this study is to clarify the impacts of adipocytokines and obesity-associated inflammatory markers on apolipoprotein (apo) A1 and B in patients on statin therapy.

Methods: In 156 patients on statin therapy (age 70 ± 10 years; 73% men; LDL cholesterol 93 ± 22 mg/dl), serum levels of apoA1 and apoB, high-sensitive C-reactive protein (hs-CRP), interleukin 6 (IL-6) and adipocytokines including adiponectin, leptin and resistin were measured using respective ELISAs.

Results: Serum apoA1 levels were significantly correlated with serum adiponectin (p<0.0001) and resistin (p<0.001), but not with leptin. Inflammatory markers, such as hs-CRP (p=0.003) and IL-6 (p<0.0001), showed strong impacts on apoA1 levels. In multivariate logistic analysis, IL-6 (p=0.004) and adiponectin (p=0.02) were significant determinants for apoA1 levels. On the other hand, serum apoB levels were significantly associated with serum leptin (p<0.001), but not with other adipocytokines or inflammatory markers.

Conclusion: IL-6 and adiponectin are strong determinants for apoA1 level, and leptin is an important factor for apoB level in patients on statin therapy.